Oric Pharmaceuticals, Inc. (ORIC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d103876dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 ORIC PHARMACEUTICALS, INC. 2020 EQUITY INCENTIVE PLAN (as amended and restated effective as of June 18, 2026) 1. Purposes of the Plan . The purposes of this Plan are: • to attract and retain the best available personnel for
How this was made
The 30-second read
Why it matters
The only concrete, detailed content shown is the amended and restated 2020 Equity Incentive Plan effective June 18, 2026; the excerpt does not provide the specific personnel changes or award economics.
Market read
This is a governance/compensation filing; without the missing exhibit details, it is unlikely to drive a major immediate repricing.
What to watch
Traders should verify the full 8-K exhibits for the specific director/officer changes and any material compensation terms; those details could change dilution or governance risk more than the plan boilerplate suggests.
Background
The SEC 8-K cites Item 5.02 (director/officer departures, elections, appointments, and compensatory arrangements) and Item 5.07 (matters submitted to a vote).
Ticker impact
ORIC filed an 8-K for director/officer departures and elections plus adoption of an amended 2020 equity incentive plan effective June 18, 2026.
Likely limited immediate price impact unless the omitted exhibits specify material compensation terms or named executive changes.
The provided text is largely plan boilerplate and does not include the specific personnel changes or quantitative award details referenced by Item 5.02/5.07.
Market effects
Minimal sector read-through; this is company-specific governance/compensation documentation.
None indicated.
None indicated.
Counterpoint
This filing may be mostly administrative (plan restatement/standard 8-K items) with little incremental information for traders absent named executive details or award sizes.
Key entities
- companyOric Pharmaceuticals, Inc.
Subject of the SEC 8-K; filed for director/officer changes and equity incentive plan amendment/restatement.
